Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NEOMERO-2. Pharmacokinetics and safety of Meropenem in infants below 90 days of age (inclusive) with probable and confirmed meningitis: A European Multicenter Phase I-II Trial

Next Previous
Trial Profile

NEOMERO-2. Pharmacokinetics and safety of Meropenem in infants below 90 days of age (inclusive) with probable and confirmed meningitis: A European Multicenter Phase I-II Trial

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meropenem (Primary)
  • Indications Bacterial meningitis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms NeoMero-2

    • Most Recent Events

    • 19 Apr 2018 Results of joint analysis of NCT01551394 and NCT01554124 trials evaluating the plasma and CSF pharmacokinetics of meropenem and the association between PK and clinical outcomes in babies with late-onset sepsis published in the Journal of Antimicrobial Chemotherapy
    • 08 Feb 2016 The trial status is given as active, no longer recruiting in UKCRN,and completed in NCT; retained as per NCT because it includes more locations than UKCRN
    • 20 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top